Literature DB >> 2408149

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

T G Lugo1, A M Pendergast, A J Muller, O N Witte.   

Abstract

Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2408149     DOI: 10.1126/science.2408149

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  305 in total

Review 1.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Authors:  B J Druker; N B Lydon
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1.

Authors:  T Hosooka; T Noguchi; H Nagai; T Horikawa; T Matozaki; M Ichihashi; M Kasuga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.

Authors:  Raphaël Beck; Rozangela Curi Pedrosa; Nicolas Dejeans; Christophe Glorieux; Philippe Levêque; Bernard Gallez; Henryk Taper; Stéphane Eeckhoudt; Laurent Knoops; Pedro Buc Calderon; Julien Verrax
Journal:  Invest New Drugs       Date:  2010-05-08       Impact factor: 3.850

4.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.

Authors:  Wei-Gang Tong; Zeev Estrov; Yongtao Wang; Susan O'Brien; Stefan Faderl; David M Harris; Quin Van Pham; Inbal Hazan-Halevy; Zhiming Liu; Patricia Koch; Hagop Kantarjian; Michael J Keating; Alessandra Ferrajoli
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

6.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 7.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

Review 8.  Oncogenic gene fusions in epithelial carcinomas.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Curr Opin Genet Dev       Date:  2009-02-21       Impact factor: 5.578

9.  Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Authors:  Mats Hardling; Yuan Wei; Lars Palmqvist; Birgitta Swolin; Dick Stockelberg; Bengt Gustavsson; Kerstin Ekeland-Sjöberg; Hans Wadenvik; Anne Ricksten
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.